AUS
NZ
UK
CA
USA
IND
Belite Bio, Inc (NASDAQ: BLTE), a distinguished player in the realm of clinical-stage biopharmaceutical drug development, has achieved a significant milestone with its lead pipeline candidate, Tinlarebant. The company proudly announces that Tinlarebant has been granted Sakigake Designation by the Ministry of Health, Labour and Welfare in Japan (MHLW) for the treatment of Stargardt Disease type 1 (STGD1).
Sakigake designation, established by MHLW, serves as a catalyst for expediting the drug approval process in Japan, particularly for innovative drugs addressing serious diseases. This designation prioritizes the consultation process, streamlines review procedures, and facilitates early access to promising treatments for patients in Japan. Belite Bio's Tinlarebant has earned this prestigious designation owing to its potential to address the unmet medical needs of individuals suffering from STGD1.
Tinlarebant, also known as LBS-008, represents a novel oral therapy designed to combat the accumulation of vitamin A-based toxins, known as bisretinoids, implicated in retinal diseases such as STGD1 and advanced Dry Age-related Macular Degeneration (AMD). By targeting retinol binding protein 4 (RBP4), Tinlarebant effectively modulates retinol levels, thereby mitigating the formation of bisretinoids and halting disease progression. The drug has garnered widespread recognition, securing Fast Track Designation, Rare Pediatric Disease designation, and Orphan Drug Designation in multiple regions, including the U.S., Europe, and Japan.
Stargardt Disease type 1 (STGD1) stands as the most prevalent inherited retinal dystrophy, afflicting both adults and children. Characterized by mutations in the retina-specific gene ABCA4, STGD1 triggers the progressive accumulation of bisretinoids, culminating in retinal cell death and gradual central vision loss. Belite Bio's focus on addressing the shared pathophysiology between STGD1 and advanced Dry AMD underscores the company's commitment to delivering impactful therapies for debilitating retinal conditions.
Dry AMD, a leading cause of vision impairment among the elderly, progresses to its advanced stage, Geographic Atrophy (GA), resulting in irreversible vision loss. With no FDA-approved orally administered treatments available for GA, Tinlarebant's potential to mitigate bisretinoid accumulation offers hope for millions of patients worldwide.
Belite Bio's dedication to pioneering novel therapeutics targeting retinal degenerative diseases reflects its mission to address critical unmet medical needs. Through initiatives like the ongoing Phase 3 study, PHOENIX, evaluating Tinlarebant's safety and efficacy in GA patients, the company continues to advance its commitment to transforming the landscape of retinal care.
